{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T19:50:30Z","timestamp":1793994630079,"version":"4.8.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Antibody-secreting cells (ASCs) play a central role in the pathophysiology of systemic lupus erythematosus (SLE). This single-arm, open-label, phase 2 clinical trial aims to evaluate the safety and efficacy of the ASC-depleting anti-CD38 monoclonal antibody daratumumab in patients with SLE (NCT04810754). The primary endpoint is the reduction in serum anti-double-stranded DNA (anti-dsDNA) antibody levels at week 12. Key secondary end points include safety, clinical efficacy, and immunologic changes. Ten female patients with active disease and inadequate responses to at least two immunosuppressive drugs have received eight subcutaneous injections of 1800 mg daratumumab weekly, with dexamethasone as premedication (20\u2009mg for first two injections, then 10\u2009mg). By week 12, anti-dsDNA antibody levels have been reduced by a median of 109.6 IU\/ml (95% CI 38.1 \u2013 274.5). The treatment resulted in rapid and sustained clinical improvements across all patients and organ domains, reflected by a 100% SRI-4 (Systemic Lupus Erythematosus Responder Index-4) response rate at week 12. Hypogammaglobulinemia occurred in 5\/10 patients, requiring immunoglobulin substitution. Daratumumab treatment has depleted circulating ASCs, reduced type I interferon activity, and profoundly modulated the T-cell responses. These findings highlight the pivotal role of ASCs in SLE pathogenesis and support daratumumab as therapeutic option for SLE.<\/jats:p>","DOI":"10.1038\/s41467-026-69112-w","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:45:35Z","timestamp":1770079535000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Daratumumab in systemic lupus erythematosus: a single-arm phase 2 trial"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3553-6406","authenticated-orcid":false,"given":"Lennard","family":"Ostendorf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Zernicke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Klotsche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Kempkens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne E.","family":"Beenken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0434-7832","authenticated-orcid":false,"given":"Robert","family":"Biesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyu","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4821-1543","authenticated-orcid":false,"given":"Laleh","family":"Khodadadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela Maria","family":"Guerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6097-5422","authenticated-orcid":false,"given":"Frederik","family":"Heinrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6179-0670","authenticated-orcid":false,"given":"Pawel","family":"Durek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd-R\u00fcdiger","family":"Burmester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7566-4325","authenticated-orcid":false,"given":"Gerhard","family":"Kr\u00f6nke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3584-5292","authenticated-orcid":false,"given":"Falk","family":"Hiepe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8015-6907","authenticated-orcid":false,"given":"Mir-Farzin","family":"Mashreghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1193-0097","authenticated-orcid":false,"given":"Tobias","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,3]]},"reference":[{"key":"69112_CR1","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1016\/S0140-6736(24)00398-2","volume":"403","author":"A Hoi","year":"2024","unstructured":"Hoi, A., Igel, T., Mok, C. C. & Arnaud, L. Systemic lupus erythematosus.  Lancet 403, 2326\u20132338 (2024).","journal-title":"Lancet"},{"key":"69112_CR2","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/40540","volume":"388","author":"RA Manz","year":"1997","unstructured":"Manz, R. A., Thiel, A. & Radbruch, A. Lifetime of plasma cells in the bone marrow. Nature 388, 133\u2013134 (1997).","journal-title":"Nature"},{"key":"69112_CR3","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1136\/ard.2008.096495","volume":"69","author":"AM Jacobi","year":"2010","unstructured":"Jacobi, A. M. et al. HLA-DR high\/CD27 high plasmablasts indicate active disease in patients with systemic lupus erythematosus. Ann. rheum. dis. 69, 305\u2013308 (2010).","journal-title":"Ann. rheum. dis."},{"key":"69112_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-46053-w","volume":"15","author":"W Chen","year":"2024","unstructured":"Chen, W. et al. Distinct transcriptomes and autocrine cytokines underpin maturation and survival of antibody-secreting cells in systemic lupus erythematosus. Nat. commun. 15, 1899 (2024).","journal-title":"Nat. commun."},{"key":"69112_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-48570-0","volume":"15","author":"M Ferreira-Gomes","year":"2024","unstructured":"Ferreira-Gomes, M. et al. Recruitment of plasma cells from IL-21-dependent and IL-21-independent immune reactions to the bone marrow. Nat. commun. 15, 4182 (2024).","journal-title":"Nat. commun."},{"key":"69112_CR6","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13075-015-0551-3","volume":"17","author":"A Taddeo","year":"2015","unstructured":"Taddeo, A. et al. Long-lived plasma cells are early and constantly generated in New Zealand Black\/New Zealand White F1 mice and their therapeutic depletion requires a combined targeting of autoreactive plasma cells and their precursors. Arthritis res. ther. 17, 39 (2015).","journal-title":"Arthritis res. ther."},{"key":"69112_CR7","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1084\/jem.20040168","volume":"199","author":"BF Hoyer","year":"2004","unstructured":"Hoyer, B. F. et al. Short-lived Plasmablasts and Long-lived Plasma Cells Contribute to Chronic Humoral Autoimmunity in NZB\/W Mice.  J. Exp. Med. 199, 1577\u20131584 (2004).","journal-title":"J. Exp. Med."},{"key":"69112_CR8","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/nrrheum.2011.1","volume":"7","author":"F Hiepe","year":"2011","unstructured":"Hiepe, F. et al. Long-lived autoreactive plasma cells drive persistent autoimmune inflammation. Nat. Rev. Rheumatol. 7, 170\u2013178 (2011).","journal-title":"Nat. Rev. Rheumatol."},{"key":"69112_CR9","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/s41584-021-00601-6","volume":"17","author":"P Maschmeyer","year":"2021","unstructured":"Maschmeyer, P. et al. Immunological memory in rheumatic inflammation \u2014 a roadblock to tolerance induction. Nat. rev. rheumatol. 17, 291\u2013305 (2021).","journal-title":"Nat. rev. rheumatol."},{"key":"69112_CR10","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/nrneph.2016.20","volume":"12","author":"F Hiepe","year":"2016","unstructured":"Hiepe, F. & Radbruch, A. Plasma cells as an innovative target in autoimmune disease with renal manifestations. Nat. rev. nephrol. 12, 232\u2013240 (2016).","journal-title":"Nat. rev. nephrol."},{"key":"69112_CR11","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1136\/annrheumdis-2013-203455","volume":"72","author":"Q Cheng","year":"2013","unstructured":"Cheng, Q. et al. Autoantibodies from long-lived \u2018memory\u2019 plasma cells of NZB\/W mice drive immune complex nephritis. Ann. rheum. dis. 72, 2011\u20132017 (2013).","journal-title":"Ann. rheum. dis."},{"key":"69112_CR12","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1038\/nm1763","volume":"14","author":"K Neubert","year":"2008","unstructured":"Neubert, K. et al. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat. med. 14, 748\u2013755 (2008).","journal-title":"Nat. med"},{"key":"69112_CR13","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1182\/blood-2008-07-168286","volume":"113","author":"T Alexander","year":"2009","unstructured":"Alexander, T. et al. Depletion of autoreactive immunologic memory followed by autologous hematopoietic stem cell transplantation in patients with refractory SLE induces long-term remission through de novo generation of a juvenile and tolerant immune system. Blood 113, 214\u2013223 (2009).","journal-title":"Blood"},{"key":"69112_CR14","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1136\/annrheumdis-2014-206016","volume":"74","author":"T Alexander","year":"2015","unstructured":"Alexander, T. et al. The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus. Ann. rheum. dis. 74, 1474\u20131478 (2015).","journal-title":"Ann. rheum. dis."},{"key":"69112_CR15","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1056\/NEJMc2407150","volume":"391","author":"T Alexander","year":"2024","unstructured":"Alexander, T., Kr\u00f6nke, J., Cheng, Q., Keller, U. & Kr\u00f6nke, G. Teclistamab-induced remission in refractory systemic lupus erythematosus. N. Engl. J. Med 391, 864\u2013866 (2024).","journal-title":"N. Engl. J. Med"},{"key":"69112_CR16","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1056\/NEJMc2408786","volume":"391","author":"M Hagen","year":"2024","unstructured":"Hagen, M. et al. BCMA-targeted t-cell\u2013engager therapy for autoimmune disease. N. Engl. J. Med 391, 867\u2013869 (2024).","journal-title":"N. Engl. J. Med"},{"key":"69112_CR17","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/imr.12389","volume":"270","author":"NWCJ Van De Donk","year":"2016","unstructured":"Van De Donk, N. W. C. J. et al. Monoclonal antibodies targeting CD 38 in hematological malignancies and beyond. Immunological Rev. 270, 95\u2013112 (2016).","journal-title":"Immunological Rev."},{"key":"69112_CR18","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/NEJMoa1506348","volume":"373","author":"HM Lokhorst","year":"2015","unstructured":"Lokhorst, H. M. et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. N. Engl. J. Med 373, 1207\u20131219 (2015).","journal-title":"N. Engl. J. Med"},{"key":"69112_CR19","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1056\/NEJMoa2023325","volume":"383","author":"L Ostendorf","year":"2020","unstructured":"Ostendorf, L. et al. Targeting CD38 with Daratumumab in Refractory Systemic Lupus Erythematosus. N. Engl. J. Med 383, 1149\u20131155 (2020).","journal-title":"N. Engl. J. Med"},{"key":"69112_CR20","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1038\/s41591-023-02479-1","volume":"29","author":"D Roccatello","year":"2023","unstructured":"Roccatello, D. et al. Daratumumab monotherapy for refractory lupus nephritis. Nat. Med 29, 2041\u20132047 (2023).","journal-title":"Nat. Med"},{"key":"69112_CR21","doi-asserted-by":"publisher","first-page":"e003604","DOI":"10.1136\/rmdopen-2023-003604","volume":"9","author":"M-T Holzer","year":"2023","unstructured":"Holzer, M.-T. et al. Daratumumab for autoimmune diseases: a systematic review. RMD Open 9, e003604 (2023).","journal-title":"RMD Open"},{"key":"69112_CR22","doi-asserted-by":"crossref","unstructured":"Burns, M. et al. Dysregulated CD38 expression on peripheral blood immune cell subsets in SLE. Int. J. Mol. Sci. 22, 2424 (2021).","DOI":"10.3390\/ijms22052424"},{"key":"69112_CR23","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/j.cmet.2016.05.006","volume":"23","author":"J Camacho-Pereira","year":"2016","unstructured":"Camacho-Pereira, J. et al. CD38 Dictates Age-Related NAD Decline and mitochondrial dysfunction through an sirt3-dependent mechanism. Cell Metab. 23, 1127\u20131139 (2016).","journal-title":"Cell Metab."},{"key":"69112_CR24","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.celrep.2019.12.014","volume":"30","author":"E Katsuyama","year":"2020","unstructured":"Katsuyama, E. et al. The CD38\/NAD\/SIRTUIN1\/EZH2 Axis Mitigates Cytotoxic CD8 T Cell Function and Identifies Patients with SLE Prone to Infections. Cell Rep. 30, 112\u2013123.e4 (2020).","journal-title":"Cell Rep."},{"key":"69112_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-52617-7","volume":"15","author":"E Katsuyama","year":"2024","unstructured":"Katsuyama, E. et al. CD38 in SLE CD4 T cells promotes Ca2+ flux and suppresses interleukin-2 production by enhancing the expression of GM2 on the surface membrane. Nat. commun. 15, 8304 (2024).","journal-title":"Nat. commun."},{"key":"69112_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22312-y","volume":"12","author":"N Buang","year":"2021","unstructured":"Buang, N. et al. Type I interferons affect the metabolic fitness of CD8+ T cells from patients with systemic lupus erythematosus. Nat. commun. 12, 1980 (2021).","journal-title":"Nat. commun."},{"key":"69112_CR27","doi-asserted-by":"publisher","DOI":"10.1172\/JCI179561","volume":"134","author":"N M\u00fclling","year":"2024","unstructured":"M\u00fclling, N. et al. Inhibiting the NADase CD38 improves cytomegalovirus-specific CD8+ T cell functionality and metabolism. J. Clin. Investig. 134, e179561 (2024).","journal-title":"J. Clin. Investig."},{"key":"69112_CR28","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abo4271","volume":"8","author":"P-M Chen","year":"2022","unstructured":"Chen, P.-M. et al. CD38 reduces mitochondrial fitness and cytotoxic T cell response against viral infection in lupus patients by suppressing mitophagy. Sci. Adv. 8, eabo4271 (2022).","journal-title":"Sci. Adv."},{"key":"69112_CR29","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2021-000538","volume":"8","author":"RF Van Vollenhoven","year":"2021","unstructured":"Van Vollenhoven, R. F. et al. 2021 DORIS definition of remission in SLE: final recommendations from an international task force. Lupus sci. med 8, e000538 (2021).","journal-title":"Lupus sci. med"},{"key":"69112_CR30","doi-asserted-by":"publisher","first-page":"e370","DOI":"10.1016\/S2352-3026(20)30070-3","volume":"7","author":"M-V Mateos","year":"2020","unstructured":"Mateos, M.-V. et al. Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial.  lancet Haematol. 7, e370\u2013e380 (2020).","journal-title":"lancet Haematol."},{"key":"69112_CR31","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/S1470-2045(21)00128-5","volume":"22","author":"MA Dimopoulos","year":"2021","unstructured":"Dimopoulos, M. A. et al. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial.  lancet Oncol. 22, 801\u2013812 (2021).","journal-title":"lancet Oncol."},{"key":"69112_CR32","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1182\/blood.2019000667","volume":"134","author":"SZ Usmani","year":"2019","unstructured":"Usmani, S. Z. et al. Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma. Blood 134, 668\u2013677 (2019).","journal-title":"Blood"},{"key":"69112_CR33","doi-asserted-by":"publisher","first-page":"7498","DOI":"10.1158\/1078-0432.CCR-17-2027","volume":"23","author":"J Krejcik","year":"2017","unstructured":"Krejcik, J. et al. Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab. Clin. cancer Res. 23, 7498\u20137511 (2017).","journal-title":"Clin. cancer Res."},{"key":"69112_CR34","doi-asserted-by":"publisher","first-page":"e1486948","DOI":"10.1080\/2162402X.2018.1486948","volume":"7","author":"J Ghose","year":"2018","unstructured":"Ghose, J. et al. Daratumumab induces CD38 internalization and impairs myeloma cell adhesion. OncoImmunology 7, e1486948 (2018).","journal-title":"OncoImmunology"},{"key":"69112_CR35","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adi0944","volume":"16","author":"JFE Koenig","year":"2024","unstructured":"Koenig, J. F. E. et al. Type 2\u2013polarized memory B cells hold allergen-specific IgE memory. Sci. Transl. Med. 16, eadi0944 (2024).","journal-title":"Sci. Transl. Med."},{"key":"69112_CR36","doi-asserted-by":"publisher","first-page":"e202302214","DOI":"10.26508\/lsa.202302214","volume":"6","author":"D Verhoeven","year":"2023","unstructured":"Verhoeven, D. et al. B-cell targeting with anti-CD38 daratumumab: implications for differentiation and memory responses. Life Sci. Alliance 6, e202302214 (2023).","journal-title":"Life Sci. Alliance"},{"key":"69112_CR37","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1136\/annrheumdis-2015-207776","volume":"75","author":"C Von Spee-Mayer","year":"2016","unstructured":"Von Spee-Mayer, C. et al. Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus. Ann. rheum. dis. 75, 1407\u20131415 (2016).","journal-title":"Ann. rheum. dis."},{"key":"69112_CR38","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1002\/eji.201344280","volume":"45","author":"K Ohl","year":"2015","unstructured":"Ohl, K. & Tenbrock, K. Regulatory T cells in systemic lupus erythematosus. Eur. J. immunol. 45, 344\u2013355 (2015).","journal-title":"Eur. J. immunol."},{"key":"69112_CR39","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41577-024-00994-x","volume":"24","author":"TS Sumida","year":"2024","unstructured":"Sumida, T. S., Cheru, N. T. & Hafler, D. A. The regulation and differentiation of regulatory T cells and their dysfunction in autoimmune diseases. Nat. rev. immunol. 24, 503\u2013517 (2024).","journal-title":"Nat. rev. immunol."},{"key":"69112_CR40","doi-asserted-by":"publisher","first-page":"4290","DOI":"10.1158\/1078-0432.CCR-16-3192","volume":"23","author":"X Feng","year":"2017","unstructured":"Feng, X. et al. Targeting CD38 suppresses induction and function of T regulatory cells to mitigate immunosuppression in multiple myeloma. Clin. Cancer Res 23, 4290\u20134300 (2017).","journal-title":"Clin. Cancer Res"},{"key":"69112_CR41","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1084\/jem.20131556","volume":"211","author":"S Srivastava","year":"2014","unstructured":"Srivastava, S., Koch, M. A., Pepper, M. & Campbell, D. J. Type I interferons directly inhibit regulatory T cells to allow optimal antiviral T cell responses during acute LCMV infection. J. Exp. Med. 211, 961\u2013974 (2014).","journal-title":"J. Exp. Med."},{"key":"69112_CR42","doi-asserted-by":"publisher","first-page":"e1006985","DOI":"10.1371\/journal.ppat.1006985","volume":"14","author":"A Gangaplara","year":"2018","unstructured":"Gangaplara, A. et al. Type I interferon signaling attenuates regulatory T cell function in viral infection and in the tumor microenvironment. PLoS Pathog. 14, e1006985 (2018).","journal-title":"PLoS Pathog."},{"key":"69112_CR43","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.immuni.2010.12.002","volume":"33","author":"YM Kerdiles","year":"2010","unstructured":"Kerdiles, Y. M. et al. Foxo transcription factors control regulatory T cell development and function. Immunity 33, 890\u2013904 (2010).","journal-title":"Immunity"},{"key":"69112_CR44","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1038\/s41590-022-01152-y","volume":"23","author":"TS Sumida","year":"2022","unstructured":"Sumida, T. S. et al. Type I interferon transcriptional network regulates expression of coinhibitory receptors in human T cells. Nat. Immunol. 23, 632\u2013642 (2022).","journal-title":"Nat. Immunol."},{"key":"69112_CR45","doi-asserted-by":"publisher","unstructured":"Rubio, J. et al. Expanded CD8+CD38+ T cell population in patients with systemic lupus erythematosus is linked to increased infection rates: A prospective study. ACR open rheumatology acr2.11725 https:\/\/doi.org\/10.1002\/acr2.11725 (2024).","DOI":"10.1002\/acr2.11725"},{"key":"69112_CR46","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2308917","volume":"390","author":"F M\u00fcller","year":"2024","unstructured":"M\u00fcller, F. et al. CD19 CAR T-cell therapy in autoimmune disease \u2014 A case series with follow-up. N. Engl. J. Med 390, 687\u2013700 (2024).","journal-title":"N. Engl. J. Med"},{"key":"69112_CR47","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1136\/ard-2023-224152","volume":"82","author":"T Alexander","year":"2023","unstructured":"Alexander, T. et al. Sustained responses after anti-CD38 treatment with daratumumab in two patients with refractory systemic lupus erythematosus. Ann. Rheum. Dis. 82, 1497\u20131499 (2023).","journal-title":"Ann. Rheum. Dis."},{"key":"69112_CR48","unstructured":"Janssen Biotech. Dosing and Administration Guide Darzalex Faspro https:\/\/www.darzalexhcp.com\/pdfs\/dosing-and-administration-guide-faspro.pdf accessed 18.11.2025."},{"key":"69112_CR49","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1136\/annrheumdis-2018-214819","volume":"78","author":"M Aringer","year":"2019","unstructured":"Aringer, M. et al. 2019 european league against rheumatism\/american college of rheumatology classification criteria for systemic lupus erythematosus. Ann. Rheum. Dis. 78, 1151\u20131159 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"69112_CR50","unstructured":"Department of health and human services, national institutes of health, national cancer institute. common terminology criteria for adverse events (CTCAE) version 5. in (2017)."},{"key":"69112_CR51","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1191\/096120399680411281","volume":"8","author":"M Petri","year":"1999","unstructured":"Petri, M., Buyon, J. & Kim, M. Classification and definition of major flares in SLE clinical trials. Lupus 8, 685\u2013691 (1999).","journal-title":"Lupus"},{"key":"69112_CR52","doi-asserted-by":"publisher","first-page":"2708","DOI":"10.1002\/eji.202170126","volume":"51","author":"A Cossarizza","year":"2021","unstructured":"Cossarizza, A. et al. Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition). Eur. J. immunol. 51, 2708\u20133145 (2021).","journal-title":"Eur. J. immunol."},{"key":"69112_CR53","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/s41586-021-04142-6","volume":"600","author":"M Witkowski","year":"2021","unstructured":"Witkowski, M. et al. Untimely TGF\u03b2 responses in COVID-19 limit antiviral functions of NK cells. Nature 600, 295\u2013301 (2021).","journal-title":"Nature"},{"key":"69112_CR54","unstructured":"R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing (2021)."},{"key":"69112_CR55","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/nbt.4096","volume":"36","author":"A Butler","year":"2018","unstructured":"Butler, A., Hoffman, P., Smibert, P., Papalexi, E. & Satija, R. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat. Biotechnol. 36, 411\u2013420 (2018).","journal-title":"Nat. Biotechnol."},{"key":"69112_CR56","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1038\/s41592-019-0619-0","volume":"16","author":"I Korsunsky","year":"2019","unstructured":"Korsunsky, I. et al. Fast, sensitive and accurate integration of single-cell data with Harmony. Nat. Methods 16, 1289\u20131296 (2019).","journal-title":"Nat. Methods"},{"key":"69112_CR57","doi-asserted-by":"publisher","first-page":"47","DOI":"10.12688\/f1000research.22139.1","volume":"9","author":"N Borcherding","year":"2020","unstructured":"Borcherding, N., Bormann, N. L. & Kraus, G. scRepertoire: An R-based toolkit for single-cell immune receptor analysis. F1000Res 9, 47 (2020).","journal-title":"F1000Res"},{"key":"69112_CR58","doi-asserted-by":"publisher","first-page":"5535","DOI":"10.1093\/bioinformatics\/btaa1011","volume":"36","author":"DG Bunis","year":"2021","unstructured":"Bunis, D. G., Andrews, J., Fragiadakis, G. K., Burt, T. D. & Sirota, M. dittoSeq: universal user-friendly single-cell and bulk RNA sequencing visualization toolkit. Bioinformatics 36, 5535\u20135536 (2021).","journal-title":"Bioinformatics"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-69112-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-69112-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-69112-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T12:04:42Z","timestamp":1770120282000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-69112-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,3]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["69112"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-69112-w","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,3]]},"assertion":[{"value":"11 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"RB received honoraria from AstraZeneca and G.S.K. F.H. received honoraria from AstraZeneca. T.A. received study support from Janssen-Cilag GmbH and honoraria from Amgen, AstraZeneca and G.S.K. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1312"}}